Overview

XTX202 in Patients With Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Xilio Development, Inc.